Status:
COMPLETED
Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL
Lead Sponsor:
CSL Limited
Conditions:
Acute Coronary Syndromes
Eligibility:
All Genders
30-75 years
Phase:
PHASE2
Brief Summary
Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inabil...
Eligibility Criteria
Inclusion
- Male or female 30 - 75 years of age
- Recent acute coronary syndrome, defined as unstable angina, non-Q wave myocardial infarction, or ST elevation indicative of myocardial infarction, within the last 14 days
Exclusion
- \>50% stenosis by visual angiographic estimation in the left main artery
- Renal insufficiency
- Severe liver disease
- Congestive heart failure as defined by the NYHA classification as functional Class III or Class IV
- Previous or planned coronary artery bypass surgery
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00225719
Start Date
July 1 2005
Last Update
November 10 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montreal Heart Institute
Montreal, Quebec, Canada, H1T 1C8